BeiGene Ltd. ADR (BGNE) News
Filter BGNE News Items
BGNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BGNE News Highlights
- BGNE's 30 day story count now stands at 36.
- Over the past 21 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- DRUG, DECK and INTU are the most mentioned tickers in articles about BGNE.
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemiaBeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare blood cancer. As of February 1st, 2023, BRUKINSA will be included on the List of Medications reimbursed under the Régie de l'assurance |
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer CareBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., February 03, 2023--BeiGene has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being. |
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 40% Undervaluation?Today we will run through one way of estimating the intrinsic value of BeiGene, Ltd. ( NASDAQ:BGNE ) by taking the... |
BeiGene to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, February 01, 2023--BeiGene announced that the Company will participate in two upcoming investor conferences. |
BeiGene: Watch FDA Approval And ValuationsBeiGene''s BRUKINSA has recently obtained approval from the FDA for the treatment of SLL and CLL. See why I rate BGNE stock as a buy. |
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For FridaySVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE ) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in pre-market trading. Raymond James cut the price target for Wintrust Financial Corporation (NASDAQ: WTFC ) from $118 to $110. Raymond James analyst David Long maintained a Strong Buy rating. Wintrust Financial shares gained 2.4% to close at $84.77 on Thursday. Keybanc cut the price target for Bill.com Holdings, Inc. (NASDAQ: BILL ) from $175 to $125. Keybanc analyst Josh Beck maintained an Overweight rating on the stock. Bill.com shares fell 3.7% to close at $99.72 on Thursday. Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU ) from $425 to … Full story available on Benzinga.com |
FDA Approves BeiGene''s Brukinsa For Chronic Lymphocytic LeukemiaThe FDA has approved BeiGene Ltd''s (NASDAQ: BGNE ) Bruton''s tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "With four US approvals in just over three years and demonstrated superiority versus ibrutinib in the final progression-free … Full story available on Benzinga.com |
BeiGene (BGNE) Presents At 41st Annual Healthcare Conference - Slideshow (NASDAQ:BGNE)The following slide deck was published by BeiGene, Ltd. |
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall SurvivalJazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months. |
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic LeukemiaThe FDA has approved BeiGene Ltd's (NASDAQ: BGNE) Bruton's tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "With four US approvals in just over three years and demonstrated superiority versus ibrutinib in the final progression-free survival (PFS) analysis of the ALPINE trial, we believe BRUKINSA is well-positioned to become the BTKi of choice across multiple indications," said Mehrdad Mobasher, Chief Medical Off |